{"id":180654,"date":"2026-08-03T11:51:04","date_gmt":"2026-08-03T06:21:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=180654"},"modified":"2026-08-03T11:51:08","modified_gmt":"2026-08-03T06:21:08","slug":"aarti-drugs-q1-results-fy27-pat-rs-50-cr","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/","title":{"rendered":"Aarti Drugs Q1 Results FY27: PAT at Rs 50 Cr for June 2026 Quarter"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Aarti Drugs Q1 FY27: PAT Rs 50 Cr, -7.12% YoY. Revenue Rs 702 Cr, +19.01% YoY. Stock at Rs 424 (up 0.30%).<\/em><\/p>\n<p>The Aarti Drugs Q1 results FY27 show consolidated revenue of Rs 702 Cr for the quarter ended 30 June 2026, +19.01% from Rs 590 Cr in Q1 FY26, as <a href=\"https:\/\/univest.in\/stocks\/aartidrugs\/aarti-drugs-ltd-share-price-today\">Aarti Drugs<\/a> reported its numbers on 31 July 2026.<\/p>\n<p>Aarti Drugs posted a net profit (PAT) of Rs 50 Cr for the quarter, against Rs 53 Cr a year earlier. Shares traded around Rs 424 on the NSE, up 0.30% on the day, as investors weighed the print against trends in the pharmaceuticals sector. Here is a full breakdown of the financial highlights, key business factors, dividend status, outlook and risks.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=aarti-drugs-q1-fy27-results\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Aarti_Drugs_Q1_Results_FY27_Financial_Highlights\" title=\"Aarti Drugs Q1 Results FY27 Financial Highlights\">Aarti Drugs Q1 Results FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Aarti_Drugs_Q1_FY27_Performance_Analysis\" title=\"Aarti Drugs Q1 FY27 Performance Analysis\">Aarti Drugs Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Aarti_Drugs_Q1_FY27_Key_Business_Factors\" title=\"Aarti Drugs Q1 FY27: Key Business Factors\">Aarti Drugs Q1 FY27: Key Business Factors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#1_Revenue_Growth_Trajectory\" title=\"1. Revenue Growth Trajectory\">1. Revenue Growth Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#2_Gross_Margin_and_Cost_Trends\" title=\"2. Gross Margin and Cost Trends\">2. Gross Margin and Cost Trends<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#3_Bottom_Line_and_Earnings_Quality\" title=\"3. Bottom Line and Earnings Quality\">3. Bottom Line and Earnings Quality<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Aarti_Drugs_Outlook_for_FY27\" title=\"Aarti Drugs Outlook for FY27\">Aarti Drugs Outlook for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Aarti_Drugs_Stock_Performance_After_the_Results\" title=\"Aarti Drugs Stock Performance After the Results\">Aarti Drugs Stock Performance After the Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#1_Margin_and_Input_Cost_Risk\" title=\"1. Margin and Input Cost Risk\">1. Margin and Input Cost Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#2_Execution_and_Working_Capital_Risk\" title=\"2. Execution and Working Capital Risk\">2. Execution and Working Capital Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#3_Macro_and_Sector_Risk\" title=\"3. Macro and Sector Risk\">3. Macro and Sector Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Frequently_Asked_Questions_on_Aarti_Drugs_Q1_Results_FY27\" title=\"Frequently Asked Questions on Aarti Drugs Q1 Results FY27\">Frequently Asked Questions on Aarti Drugs Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#When_were_the_Aarti_Drugs_Q1_results_FY27_announced\" title=\"When were the Aarti Drugs Q1 results FY27 announced?\">When were the Aarti Drugs Q1 results FY27 announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#What_is_the_PAT_in_Aarti_Drugss_Q1_FY27_results\" title=\"What is the PAT in Aarti Drugs&#8217;s Q1 FY27 results?\">What is the PAT in Aarti Drugs&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#What_was_the_revenue_in_Aarti_Drugss_Q1_FY27_results\" title=\"What was the revenue in Aarti Drugs&#8217;s Q1 FY27 results?\">What was the revenue in Aarti Drugs&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Did_Aarti_Drugs_declare_a_dividend_with_the_Q1_FY27_results\" title=\"Did Aarti Drugs declare a dividend with the Q1 FY27 results?\">Did Aarti Drugs declare a dividend with the Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#What_is_the_outlook_for_Aarti_Drugs_after_Q1_FY27\" title=\"What is the outlook for Aarti Drugs after Q1 FY27?\">What is the outlook for Aarti Drugs after Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#How_did_the_stock_react_to_Aarti_Drugss_Q1_FY27_results\" title=\"How did the stock react to Aarti Drugs&#8217;s Q1 FY27 results?\">How did the stock react to Aarti Drugs&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-q1-results-fy27-pat-rs-50-cr\/#Is_Aarti_Drugs_a_good_buy_after_the_Q1_FY27_results\" title=\"Is Aarti Drugs a good buy after the Q1 FY27 results?\">Is Aarti Drugs a good buy after the Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Aarti_Drugs_Q1_Results_FY27_Financial_Highlights\"><\/span><strong>Aarti Drugs Q1 Results FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below summarises Aarti Drugs&#8217;s consolidated numbers for the quarter against the year ago period.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27 (Jun 2026)<\/th>\n<th>Q1 FY26 (Jun 2025)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>Rs 702 Cr<\/td>\n<td>Rs 590 Cr<\/td>\n<td>+19.01%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td>Rs 79 Cr<\/td>\n<td>Rs 59 Cr<\/td>\n<td>+34.33%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit Margin<\/td>\n<td>11.3%<\/td>\n<td>10.0%<\/td>\n<td>+1.3 pts<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (PAT)<\/td>\n<td>Rs 50 Cr<\/td>\n<td>Rs 53 Cr<\/td>\n<td>-7.12%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit Margin<\/td>\n<td>7.1%<\/td>\n<td>9.0%<\/td>\n<td>-1.9 pts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Aarti_Drugs_Q1_FY27_Performance_Analysis\"><\/span><strong>Aarti Drugs Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Revenue growth was the standout number for the quarter. Sales rose +19.01% year on year to Rs 702 Cr, up from Rs 590 Cr in the year ago period, as demand held firm through the June quarter.<\/p>\n<p>Margins expanded through the June quarter. Gross profit rose +34.33% year on year to Rs 79 Cr (11.3% margin), a faster clip than the revenue increase, which points to better cost absorption.<\/p>\n<p>The bottom line did not keep pace with the topline this quarter. Net profit moved -7.12% year on year to Rs 50 Cr from Rs 53 Cr in Q1 FY26, weighed down by the margin and cost trends discussed above.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aarti_Drugs_Q1_FY27_Key_Business_Factors\"><\/span><strong>Aarti Drugs Q1 FY27: Key Business Factors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Revenue_Growth_Trajectory\"><\/span><strong>1. Revenue Growth Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aarti Drugs reported revenue of Rs 702 Cr for the June 2026 quarter against Rs 590 Cr in the year ago period, a change of +19.01%. This pace of change is a primary swing factor behind the quarter&#8217;s numbers, and investors typically track whether it holds up in the following quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Gross_Margin_and_Cost_Trends\"><\/span><strong>2. Gross Margin and Cost Trends<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gross profit moved from Rs 59 Cr in Q1 FY26 to Rs 79 Cr in Q1 FY27, a change of +34.33%. In the pharmaceuticals sector, this line is sensitive to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets, and this quarter&#8217;s numbers reflect how Aarti Drugs managed that balance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Bottom_Line_and_Earnings_Quality\"><\/span><strong>3. Bottom Line and Earnings Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit moved from Rs 53 Cr in Q1 FY26 to Rs 50 Cr this quarter, down -7.12%. This is the figure that flows through to earnings per share, and it is usually the first number investors check.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Specific dividend information was not confirmed as part of this results snapshot. Investors should check the official exchange filing on the NSE or BSE website, or track the Univest Screener, for the latest dividend announcement, record date and payment date from Aarti Drugs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aarti_Drugs_Outlook_for_FY27\"><\/span><strong>Aarti Drugs Outlook for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This quarter sets the tone for the rest of FY27. If the growth in revenue and decline in net profit persist, analysts are likely to revisit their FY27 estimates for Aarti Drugs. Investors should also watch input costs and demand trends in the pharmaceuticals sector through the year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aarti_Drugs_Stock_Performance_After_the_Results\"><\/span><strong>Aarti Drugs Stock Performance After the Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aarti Drugs shares traded around Rs 424 on the NSE, up 0.30% around the time the results were in focus. The 52 week trading range was not confirmed as part of this snapshot; investors can check the live 52 week high and low, along with technical levels, on the Univest Screener before making any trading decision.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Aarti Drugs live share price and upcoming quarterly results.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors reading through Aarti Drugs&#8217;s numbers should also weigh the following risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Margin_and_Input_Cost_Risk\"><\/span><strong>1. Margin and Input Cost Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Being in the pharmaceuticals sector, Aarti Drugs remains exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal in the trend seen this quarter could pressure margins in coming quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Execution_and_Working_Capital_Risk\"><\/span><strong>2. Execution and Working Capital Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Execution risk around working capital, receivables and order timelines can cause quarter to quarter volatility in reported numbers, so this quarter&#8217;s trends should be read over a few quarters rather than in isolation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Macro_and_Sector_Risk\"><\/span><strong>3. Macro and Sector Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Broader macro factors including interest rates, currency movements and demand cycles in the pharmaceuticals sector could influence how sustainable this quarter&#8217;s trends prove to be over FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aarti Drugs Q1 results FY27 show revenue of Rs 702 Cr and Rs 50 Cr for the quarter, against Rs 590 Cr and Rs 53 Cr in Q1 FY26. Revenue growth and pressure on the bottom line were the two moving parts this quarter. Investors tracking Aarti Drugs should watch the next few quarters for confirmation of this trend and consult a SEBI-registered advisor before making investment decisions based on these numbers.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Aarti_Drugs_Q1_Results_FY27\"><\/span><strong>Frequently Asked Questions on Aarti Drugs Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_the_Aarti_Drugs_Q1_results_FY27_announced\"><\/span><strong>When were the Aarti Drugs Q1 results FY27 announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> They reflect the quarter ended 30 June 2026, with the data reported as of 31 July 2026. Investors should confirm the exact board meeting date from the official NSE or BSE filing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PAT_in_Aarti_Drugss_Q1_FY27_results\"><\/span><strong>What is the PAT in Aarti Drugs&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PAT stood at Rs 50 Cr, compared with Rs 53 Cr in Q1 FY26, a change of -7.12%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_revenue_in_Aarti_Drugss_Q1_FY27_results\"><\/span><strong>What was the revenue in Aarti Drugs&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue came in at Rs 702 Cr for the quarter, a change of +19.01%, compared with Rs 590 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Aarti_Drugs_declare_a_dividend_with_the_Q1_FY27_results\"><\/span><strong>Did Aarti Drugs declare a dividend with the Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dividend details were not confirmed as part of this results snapshot. Check the latest exchange filing on NSE or BSE, or the Univest Screener, for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_for_Aarti_Drugs_after_Q1_FY27\"><\/span><strong>What is the outlook for Aarti Drugs after Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Analysts will track whether the growth in revenue and decline in profit continue into the September 2026 quarter, along with input cost and demand trends in the pharmaceuticals sector.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_the_stock_react_to_Aarti_Drugss_Q1_FY27_results\"><\/span><strong>How did the stock react to Aarti Drugs&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Shares traded around Rs 424 on the NSE, up 0.30% as the numbers came into focus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Aarti_Drugs_a_good_buy_after_the_Q1_FY27_results\"><\/span><strong>Is Aarti Drugs a good buy after the Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The quarter shows a net profit of Rs 50 Cr on revenue of Rs 702 Cr. This article is for educational purposes only and is not investment advice. Consult a SEBI-registered advisor before making any investment decision.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Aarti Drugs Q1 results FY27: revenue Rs 702 Cr (+19.01% YoY), PAT Rs 50 Cr. Full financial highlights, key factors and outlook for the June 2026 quarter.<\/p>\n","protected":false},"author":28,"featured_media":180653,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-180654","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["180653"],"_edit_lock":["1785738070:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Aarti Drugs Q1 FY27 Results: PAT Rs 50 Cr, Revenue Rs 702 Cr"],"rank_math_description":["Aarti Drugs Q1 results FY27: revenue Rs 702 Cr (+19.01% YoY), PAT Rs 50 Cr. Full financial highlights, key factors and outlook for the June 2026 quarter."],"rank_math_focus_keyword":["Aarti Drugs Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["32841"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/aarti-drugs-q1-results-fy27-pat-rs-50-cr.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/180654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=180654"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/180654\/revisions"}],"predecessor-version":[{"id":180671,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/180654\/revisions\/180671"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/180653"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=180654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=180654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=180654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}